|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
American women of African ancestry (AA) are more likely than European-Americans (EA) to be diagnosed with aggressive, estrogen receptor (ER) negative breast tumors; mechanisms underlying these disparities are poorly understood.
|
24368439 |
2014 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We analyzed 410 primary treatment-naive breast tumors comprising 162 estrogen receptor-positive (ER+) and HER2-, 101 HER2+ and 147 triple-negative (TN) cancers.
|
30524905 |
2018 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Estrogens play a crucial role in regulating the growth and differentiation of breast cancers, with approximately two thirds of all breast tumors expressing the estrogen receptor alpha (ERalpha).
|
20427689 |
2010 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Remodeling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast tumors is novel, and given the need for better strategies to improve therapy response in relapsed ERα (+) tumors, our findings show great promise for uncovering the role that ERα-XPO1 crosstalk plays in reducing cancer recurrences.
|
30987380 |
2019 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the status of the ER pathway modulates the expression of MTA3 as well as epithelial-to-mesenchymal transition in human breast tumors.
|
14613024 |
2003 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Expression of genes coding for pS2, c-erbB2, estrogen receptor and the H23 breast tumor-associated antigen. A comparative analysis in breast cancer.
|
2194831 |
1990 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer.
|
17545528 |
2007 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Oestrogen receptor alpha (ER alpha) is traditionally measured on all breast tumour specimens to identify those patients more likely to respond to anti-oestrogens.
|
17896177 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
SRC-3 was localised within epithelial cells of breast tumour tissue and was co-localised with ER-alpha and ER-beta, (n=112).
|
17158759 |
2006 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
About 70% of breast tumors express estrogen receptor alpha (ERα), which mediates the proliferative effects of estrogens on breast epithelial cells, and are candidates for treatment with antiestrogens, steroidal or non-steroidal molecules designed to compete with estrogens and antagonize ERs.
|
27729460 |
2017 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Indeed, inhibition or down-regulation of ER reduces tumor growth in preclinical models of acquired endocrine resistance, and many patients with recurrent ER+ breast tumors progressing on one type of ER-targeted treatment still benefit from sequential endocrine treatments that target ER by a different mechanism.
|
26271713 |
2015 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Although tamoxifen treatment is associated with improved survival in patients with estrogen receptor (ER)-positive breast tumors, resistance remains an important clinical obstacle.
|
20689759 |
2010 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Differential expression of VEGF-A mRNA by 17beta-estradiol in breast tumor cells lacking classical ER-alpha may be mediated through a variant form of ER-alpha.
|
15532726 |
2004 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Observations on the presence of E domain variants of estrogen receptor-alpha in the breast tumors.
|
16941532 |
2006 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
|
16168103 |
2005 |
|
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Estrogen receptor gene methylation in human breast tumors.
|
2354445 |
1990 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In three large, independent data sets of profiled human breast tumors, the IGF-I signature was manifested in the majority of ER-negative breast tumors and in a subset (approximately 25%) of ER-positive breast tumors.
|
18757322 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Moreover, the increased risk conferred by the minor FGFR2 allele associates most strongly in oestrogen receptor alpha positive (ERα) breast tumours, suggesting a potential interaction between ERα and FGFR signalling.
|
24265722 |
2013 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
While the proliferative role of ERα in breast tumors is well characterized, it is not clear whether the antitumor activity of ERβ can be mobilized in breast cancer cells.
|
24960160 |
2014 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Our results, thus demonstrated that ER-α36 mediates nongenomic estrogen signaling through the EGFR/Src/ERK signaling pathway in ER-negative breast cancer cells and suggested that a subset of ER-negative breast tumors that expresses ER-α36, retains responsiveness to mitogenic estrogen signaling.
|
20935677 |
2011 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
One patient-derived xenograft, the estrogen receptor-positive model T126, was chosen to generate in vivo mouse models containing orthotopic breast tumors for in vivo SPECT/MRI and biodistribution studies after injection with <sup>177</sup>Lu-DOTA-Tyr<sup>3</sup>-octreotate or <sup>177</sup>Lu-DOTA-JR11.
|
28450563 |
2017 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
This review covers ER-negative breast tumor epigenetic aberrations and summarizes the major epigenetic mechanisms governing ER expression and how it impacts treatment of ER-negative breast cancer.
|
22616702 |
2012 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
NAT1, NAT2, and ESR1 expression were increased in primary breast tumor tissue compared with normal breast tissue; however, the magnitude and significance of the differences were lower for NAT2.
|
29901116 |
2018 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Initial studies in human breast cancer cell lines suggested a possible association between the absence of one allele and the absence of ER expression; subsequent analysis of allele distribution and frequency in 188 primary human breast tumor biopsies did indeed show a significant but not complete correlation between the absence of one allele and the failure to express ER.
|
2562795 |
1989 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Analysis of the ERalpha germline PvuII marker in breast cancer risk.
|
18301357 |
2008 |